

Metal complexes of flavonoids: their synthesis, characterization, and enhanced anti-oxidant and anti-cancer activities

Article

Accepted Version

Khater, M., Ravishankar, D., Greco, F. and Osborn, H. (2019) Metal complexes of flavonoids: their synthesis, characterization, and enhanced anti-oxidant and anti-cancer activities. *Future Medicinal Chemistry*, 11 (21). ISSN 1756-8927 doi: <https://doi.org/10.4155/fmc-2019-0237> Available at <https://centaur.reading.ac.uk/86372/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.4155/fmc-2019-0237>

Publisher: Future Science Group

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Metal complexes of Flavonoids: Their synthesis, characterization, and enhanced anti-oxidant and anti-cancer activities

Mai Khater^{1,2}, Divyashree Ravishankar¹, Francesca Greco¹ and Helen M.I. Osborn^{1*}

¹ School of Pharmacy, University of Reading, Whiteknights, Reading, RG6 6AD. UK

² Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Cairo, Egypt.

Abstract


Flavonoids are polyphenolic compounds of natural origin. They are extensively studied within drug discovery programmes due to their wide ranging biological activities such as anti-microbial, anti-oxidant, anti-tumor, neuroprotective and cardioprotective properties. The ability of flavonoids to coordinate with metal atoms has provided new leads for drug discovery programmes, with better pharmacological activities and clinical profiles than the parent flavonoids. In this review, the enhanced anti-oxidant and anti-cancer activities of flavonoid metal complexes versus the parent flavonoids are discussed. Possible mechanisms of action for the metal complexes, such as DNA binding and apoptosis induction, are also presented alongside an overview of the synthesis of the metal complexes, and the different techniques used for their characterization.

Keywords

Flavonoid, metal, flavonoid metal complex, anti-oxidant, anti-cancer.







Introduction

Flavonoids are phytochemicals that are mainly found in tea, citrus fruit, berries, apples and legumes. Chemically, they are polyphenolic compounds with a C₆-C₃-C₆ ring system (**Figure 1**) and they are often found in esterified or glycosylated forms [1]. It was not until the 1990's that research on flavonoids witnessed significant progress, with the number of publications increasing by approximately 6-fold, from 524 in 1990 to 3147 in 2017. As a result it is now well established that flavonoids have a wide and diverse range of biological activities [2, 3] such as anti-viral [4-6], anti-bacterial [7-10], neuroprotective [11-13], cardioprotective [14, 15], anti-oxidant [16-18] and anti-cancer [3, 19, 20] properties.



Basic skeleton of flavonoids

31



32












Figure 1. Chemical structures of flavonoids from which organometallic derivatives have been prepared

With respect to the beneficial health effects of flavonoids, the greatest impact has been seen within the anti-cancer field [2]. Flavonoids are known to interfere with an array of targets affecting cancer growth and progression. For example, they have been shown to induce cell cycle arrest and apoptosis [21] in addition to inhibiting mitotic spindle formation [22] and angiogenesis [23, 24]. Despite the advantages of having a compound that can interact with different targets, this can be a limitation due to limited selectivity. Indeed, this has been one of the biggest obstacles in the use of flavonoids as potential drugs due to its direct relation with adverse effects and poor *in vivo* toxicity profiles. However, despite the extensive research and number of structures and the activity reported for them, no flavonoid has to date reached the

market and only a limited number are in clinical investigation as anti-cancer agents, eg flavopiridol (phase-II) [25, 26], silibinin (phase-II) [27, 28], quercetin (phase-II) [29, 30] and the quercetin derivative QC12 (phase-I) [31] (**Figure 2**). Arguably, the main drug development challenge is the poor bioavailability of flavonoids, resulting from water insolubility and susceptibility to glucourinidation and/or methylation by intestinal and liver metabolism (first pass effect). There are several studies on the pharmacokinetics of flavonoids indicating their poor bioavailabilities. Wu et al., for instance, reported the absolute oral bioavailability of silibinin in rats to be approximately 0.95% [32]. In another study, flavopiridol's mean oral bioavailability following bolus intra-gavage was shown to be 20% [33]. Moreover, a study by Gugler et al. failed to detect any plasma quercetin concentrations in subjects receiving 4 g orally [34].




Figure 2. Flavonoids in clinical trials as anti-cancer agents

Due to the presence of hydroxyl and oxo groups within flavonoids, they possess metal chelating abilities that can have profound effects on their pharmacokinetic and pharmacological properties [35, 36]. The flavonoid structure, type of chelating metal and the pH of the surrounding medium

are determining factors of the preferred coordination site [37]. Metal atoms have beneficial biological properties such as chelating free radicals and binding to DNA [38]. These properties can cause synergistic effects when combined with other active chemical entities such as the flavonoids. Accordingly, metal complexation is reported to enhance the anti-oxidant, anti-proliferative and chemical properties of parent flavonoids. This review will therefore highlight important advances within the field of metal-flavonoid complexes with particular emphasis on their synthesis, methods of characterization, anti-oxidant and anti-proliferative activities.

Synthesis and characterization of flavonoid metal complexes

Flavonoid metal complexes are generally synthesized by dissolving a flavonoid salt in an alcoholic or aqueous solution, followed by the addition of the metal salt also in alcoholic or aqueous solution. The reaction can be carried out under different conditions of stirring and/or heating, normally a base is used to deprotonate the hydroxyl groups and facilitate metal coordination. The complex usually precipitates from solution and is then filtered and air dried (**Table 1**). Preparations of ferrocenyl flavonoid complexes, where the ferrocenyl moiety acts as a replacement for ring B, follow a different synthetic approach. Ferrocenyl aurones are obtained via a classic Claisen-Schmidt condensation of ferrocene carboxaldehyde and various 2-hydroxyacetophenones to obtain the corresponding ferrocene chalcones [39, 40]. The synthesized chalcones are then treated with mercury acetate in pyridine to form the ferrocenyl aurones that can be isomerized into their flavone counterparts by heating in ethanol at reflux with potassium cyanide (**Figure 3**) [39, 40].




Figure 3. Synthesis of ferrocenyl flavonoids

Kowalski et al. reported the synthesis of ferrocenyl flavonoids using the palladium-catalyzed Heck cross-coupling reaction of vinyl ferrocene with 6-bromochromones (**Figure 4**) [41].





Figure 4. Synthesis of ferrocenyl flavonoids using Pd

Structural characterization of metal complexes can be achieved using a number of methods (**Table 1**). Fourier transform infra-red (FT-IR) spectroscopy can indicate the coordination site of the metal. Complexation of the metal atom with the C=O group, for instance, causes an increase in the bond length which is manifested as a decrease in the frequency of the C=O peak. Coordination with OH groups leads to disappearance of their characteristic broad peaks ν OH at 3600-3200 cm^{-1} . However, this disappearance can be masked by the presence of other OH groups in the flavonoid structure and in the H_2O molecules incorporated in the metal sphere during complexation. Therefore, IR spectroscopy is not a helpful tool in determining which OH groups are specifically coordinated to the metal atom. ^1H NMR spectroscopic analysis can provide a better alternative where the disappearance of an OH peak from the ^1H NMR spectrum corresponds to coordination at this particular OH group. For example, the disappearance of the 5-OH peak at δ 10.52 ppm of the **lanthanum-18** complex proved coordination at this OH in ring A [42]. Heteroatom NMR spectroscopic analysis is also extremely useful. For example, Tabassum et al. used ^{119}Sn NMR spectroscopic analysis to prove the presence of stannous atoms in the synthesized bi-metallic complexes **31** and **32** (**Figure 6**) [43]. ^{195}Pt NMR spectroscopic analysis was also used to prove the structure of complex **68** [44]. Electron Paramagnetic Resonance (EPR) spectroscopy is also a helpful technique which is similar to NMR spectroscopy but more sensitive as it explores the interaction between an external magnetic field and unpaired electrons rather than nuclei. This is attributed to the fact that the amount of energy absorbed by a spinning electron is higher than that absorbed by a nucleus. This technique is more difficult to use as it requires background knowledge of subjects like quantum mechanics and mathematical techniques [45]. However it was used by Tabassum and Naso et al. groups to elucidate structures

113 of complexes (**31** and **32**) and (**33**, **37**, **VOhespiridin**, **VOsilibinin** and **VOmorin**), respectively
114 [43, 46-49].



115

116 **Figure 5.** UV absorption bands using quercetin as an illustrative example

117 Flavonoids display absorption bands in the UV-Vis region due to electronic $\pi - \pi^*$ transitions
118 [50, 51]. These transitions are responsible for the two characteristic benzoyl and cinnamoyl
119 bands of flavonoids at 240-280 nm and 320-385 nm, respectively (**Figure 5**) which are
120 bathochromically shifted after chelating with metals [52]. The observation of a red shift in one
121 band rather than the other verifies chelation with that particular ring [53-55]. Although the shift
122 is small in many cases, it gives a good insight when overlapped with the parent's spectrum. UV-
123 Vis absorption bands are also characteristic to binding in other sites. Analysis of the spectra of
124 **VOhespiridin** showed complexation with the rutinose sugar part [46]. Its electronic spectra
125 showed bands at 358, 520 and 702 nm in agreement with the three band pattern at ca. 420, 500
126 and 700 nm observed for similar sugar vanadyl(IV) complexes coordinated through deprotonated
127 cis-hydroxyl groups [56]. UV-Vis spectra can also help in detecting the stoichiometry of the
128 complex. This is achieved by monitoring the absorption intensity of the ligand through a range of
129 concentrations until the reaction is completed [46, 47, 57, 58]. Different methods can then be
130 used to represent the data, e.g. Job's method, from which ligand-metal ratio can be interpreted.
131 Similarly, fluorescence of free parents can be compared to their complexes at a specific
132 wavelength. Peaks from complexes are higher in intensity and are shifted to lower wavelengths
133 ca. 15-20 nm [55]. Elemental analysis and mass spectrometry provide complementary

information about the molecular formulae of the resulting complexes. In a recent study by Wang et al. the elemental analysis of a lead-luteolin complex was determined by scanning electron microscope (SEM) equipped with energy dispersive spectroscopy (EDS) [59]. The experimental values of weight and atomic number percentages of carbon, oxygen and lead atoms favored a 2:1 rather than 1:1 complex [59]. Analysis of the fragmentation pattern in mass spectrometry specifies how many metal atoms are coordinated in the complex [43, 60-64]. Roy et al. and Naso et al. reported the synthesis of two different complexes (**36** and **37** respectively) using the same ligand (**Luteolin**) and metal (**Vanadium**) [49, 65]. The two complexes are reported to differ in their stoichiometries and metal coordination sites which may have resulted from different ligand/metal ratios added during the synthesis process. Thus for complex **36**, two luteolin molecules are reported to chelate to the oxidovanadium(VI) group via the 4-C=O and 5-OH functionalities, whilst **37** is reported to contain only one luteolin chelated to the 3' and 4' cis-OH groups in ring B. Among the characterization techniques provided by Roy and his group, mass spectrometry data supported their structural hypothesis for complex **36**. Thus peaks at m/z 623.11, 639.89 and 658.21 represented two luteolin + one vanadium, two luteolin + vanadium oxide and two luteolin + vanadium oxide with one molecule of water, respectively. When deducing the structure of complex **37**, Nato et al. demonstrated that the FT-IR spectrum showed no change in the C=O and the C2=C3 bands, in addition to an increase of 44 cm^{-1} of the 4'-OH band, indicating chelation with ring B. EPR and UV-Vis spectra of complex **37** also supported the same findings. Thermal gravimetric studies provide information on the heat-induced decomposition of the complex as a function of temperature or time. Dehydration happens during the early stages at temperatures ranging from 100-250 °C. This is followed by decomposition of the ligand at higher temperatures (400-600 °C). At temperatures as high as 900 °C, the complex decomposes completely leaving the metal oxide [42, 43, 55, 60, 62, 66].

Nevertheless, the best proven technique to confirm a theoretical structure is X-ray crystallography. Unfortunately, it is not feasible to apply this to all synthesized molecules due to the specific crystal requirements needed to run an X-ray. Only structures of complexes **49**, **51**, **53** and **55** [67, 68] were proven by X-ray crystallography.

In general, all the used characterization methods can provide helpful information of varying importance. NMR and UV-Vis spectroscopy are the most insightful if X-ray is not feasible.

165 Other methods like IR spectroscopy, elemental analysis and mass spectrometry can complement
166 the results obtained and offer the advantages of being easy to interpret and available in most
167 research facilities.

168 **Table 1.** Summary of synthetic conditions and characterization methods for flavonoid metal complexes

<i>Flavonoid Solution</i>	<i>Metal</i>	<i>Base used and pH</i>	<i>Final product Formula</i>	<i>Characterization</i>	<i>Ref</i>
<i>Quercetin.2H₂O in EtOH</i>	NiCl ₂ ·6H ₂ O	NaOEt 6-7	Ni(Que) ₂ (H ₂ O) ₂	UV IR Elemental Analysis	[54]
	CuCl ₂ ·2H ₂ O	NaOEt 6-7	Cu(Que) ₂ (H ₂ O) ₂	UV IR Elemental Analysis	[53]
	La acetate Nd acetate Eu acetate Gd acetate Tb acetate Dy acetate Tm acetate Y acetate	NaOEt N.A.	La(Que) ₃ (H ₂ O) ₆ Nd(Que) ₃ (H ₂ O) ₆ Eu(Que) ₃ (H ₂ O) ₆ Gd(Que) ₃ (H ₂ O) ₆ Tb(Que) ₃ (H ₂ O) ₆ Dy(Que) ₃ (H ₂ O) ₆ Tm(Que) ₃ (H ₂ O) ₆ Y(Que) ₃ (H ₂ O) ₆	UV IR ¹ H NMR TG-DTA Fluorescence analysis Electrochemistry Elemental analysis	[55]

<i>[Cu(Que)₂(H₂O)₂] in MeOH</i>	SnCl ₄	N.A.	[Cu(Que) ₂ (H ₂ O) ₆ -Sn ₂ Cl ₄]	IR ¹ H, ¹³ C & ¹¹⁹ Sn NMR EPR ESI-MS TG-DTG	[43]
<i>[Zn(Que)₂(H₂O)₂] in MeOH</i>	SnCl ₄	N.A.	[Zn(Que) ₂ (H ₂ O) ₆ -Sn ₂ Cl ₄]	IR ¹ H, ¹³ C & ¹¹⁹ Sn NMR EPR ESI-MS TG-DTG	[43]
<i>Chrysin in EtOH</i>	Vanadyl acetylacetonate	N.A. 5	VO(Chry) ₂ EtOH	UV-Vis IR EPR Spectrophotometric titrations	[58]
	Ph ₃ GeBr	Na ₂ CO ₃ N.A.	Chry-Ge. C ₂ H ₆ O	IR ¹ H & ¹³ C NMR Elemental analysis	[69]

	La acetate	NaOH N.A.	La(Chry) ₂ .OAc(H ₂ O) ₇	IR ¹ H NMR Elemental analysis TG-DTG Spectrophotometric titrations	[57]
<i>Luteolin in H₂O</i>	VOSO ₄ .H ₂ O	NaOH 6	VO(Lut) ₂	UV-Vis IR ¹ H NMR ESI-MS	[65]
<i>Luteolin</i>	50% aqueous solution of VOCl ₂	NaOH 5	[VO(Lut)(H ₂ O) ₂]Na·3H ₂ O	UV-Vis IR EPR	[49]
<i>Luteolin in EtOH</i>	Mn(CH ₃ COO) ₂	N.A. 4	MnO-Lut	Elemental analysis UV-Vis IR Elemental analysis TG-DTG	[70]
<i>Hesperidin in H₂O</i>	50% aqueous solution of VOCl ₂	NaOH 12	[VO(Hesp)(OH) ₃]. Na ₄ (H ₂ O) ₃	UV-Vis IR EPR Spectrophotometric	[46]

<i>Hesperetin in EtOH</i>	$\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$	NH_3 solution 7-8	$[\text{Cu}(\text{Hespt})_2(\text{H}_2\text{O})_2] \cdot \text{H}_2\text{O}$	titrations	[66]
				UV-Vis	
				IR	
				ESI-MS	
				TG-DTG	
<i>Naringin in MeOH</i>	Cu acetate in distilled H_2O	N.A.	$[\text{Cu}(\text{Nar})]^+[\text{CH}_3\text{COO}]^-(\text{H}_2\text{O})_5$	UV-Vis	[71]
				IR	
				^1H NMR	
				ESI-MS	
				Elemental analysis	
<i>Naringenin in EtOH</i>	$\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$	NH_3 solution 7-8	$[\text{Cu}(\text{Narg})_2(\text{H}_2\text{O})_2] \cdot \text{H}_2\text{O}$	UV-Vis	[66]
				IR	
				ESI-MS	
				TG-DTG	
<i>Apigenin in EtOH</i>	$\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$	NH_3 solution 7-8	$[\text{Cu}(\text{Apg})_2(\text{H}_2\text{O})_2] \cdot \text{H}_2\text{O}$	UV-Vis	[66]
				IR	
				ESI-MS	
				TG-DTG	
<i>Silibinin in EtOH</i>	50% aqueous solution of VOCl_2	NaOCH_3 9	$\text{Na}_2[\text{VO}(\text{Sil})_2] \cdot (\text{H}_2\text{O})_6$	IR	[47]
				EPR	
				Spectrophotometric	
				titrations	

<i>Morin in MeOH</i>	50% aqueous solution of VOCl ₂	NaOCH ₃ 5	[VO(Mor) ₂ H ₂ O]. (H ₂ O) ₅	UV-Vis IR EPR Spectrophotometric titrations	[48]
<i>Kaempferol in EtOH</i>	ZnCl ₂ .2H ₂ O	NaCl 8-10	[Zn(Kaem) ₂ (H ₂ O) ₂] · H ₂ O	UV-Vis IR ¹ H NMR ESI-MS Elemental analysis	[64]
<i>Nifflcoumar sodium salt in H₂O</i>	Ce(NO ₃) ₃ .6H ₂ O La(NO ₃) ₃ .6H ₂ O Nd(NO ₃) ₃ .6H ₂ O	N.A. 4-5	Ce(NS) ₃ . (H ₂ O) ₄ La(NS) ₃ . (H ₂ O) ₄ Nd(NS) ₃ . (H ₂ O) ₆	IR ¹ H NMR Elemental analysis	[72]
<i>Nifflcoumar in H₂O</i>	Aqueous solution of ZrCl ₄	NaOH 5	Zr(Niff) ₂ (OH) ₄ (H ₂ O) ₅	IR ¹ H NMR Elemental analysis TG-DTG	[73]
<i>Warfarin in H₂O</i>	Aqueous solution of ZrCl ₄	NaOH 5	Zr(War) ₂ (OH) ₄ (H ₂ O) ₂	IR ¹ H NMR Elemental analysis TG-DTG	[73]

<i>Coumachlor in H₂O</i>	Aqueous solution of ZrCl ₄	NaOH 5	Zr(Coum) ₂ (OH) ₄ (H ₂ O) ₆	IR ¹ H NMR Elemental analysis TG-DTG	[73]
<i>1 in 50% EtOH</i>	GeO ₂ in deionized H ₂ O	NaOH 7	<i>N.A.</i>	UV-Vis IR ¹ H NMR MS Elemental analysis TG-DTG	[62]
<i>2-11 in MeOH</i>	[Ru(η ⁶ -p- cymene)Cl ₂] ₂ in CH ₂ Cl ₂	NaOMe <i>N.A.</i>	<i>N.A.</i>	¹ H & ¹³ C NMR Elemental analysis X-ray for (49, 51, 53, 55)	[67, 68]
<i>15-18 in CH₂Cl₂</i>	[Ru(η ⁶ -p- cymene)Cl ₂] ₂ in CH ₂ Cl ₂	<i>N.A.</i>	<i>N.A.</i>	UV-Vis spectra IR ¹ H NMR FAB/EI-MS	[61, 68, 74]
<i>7, 12-14 in EtOH</i>	[Ru(DMSO) ₄ Cl ₂] in EtOH	TEA <i>N.A.</i>	[Ru(DMSO) ₂ (7) ₂] ₂ NaNO ₃ (H ₂ O) ₂ [Ru(DMSO) ₂ (12) ₂] ₂ NaNO ₃ . H ₂ O [Ru(DMSO) ₂ (13) ₂]. (NO ₃) ₂ (H ₂ O) ₂ [Ru(DMSO) ₂ (14) ₂] ₂ NaNO ₃ (H ₂ O) ₅	IR ¹ H NMR ESI-MS Elemental analysis	[63]

<i>18 in EtOH</i>	La(NO ₃) ₃ .6H ₂ O	TEA N.A.	N.A.	UV-Vis spectra IR ¹ H NMR Elemental analysis TG-DAT	[42]
<i>19 in H₂O</i>	Aqueous solution of Ce La Nd	NaOH 5	Ce(19)(OH)(H ₂ O) ₂ La(19)(OH).H ₂ O Nd(19)(OH).H ₂ O	IR ¹ H & ¹³ C NMR Elemental analysis	[75]
<i>20 in EtOH</i>	Aqueous solution of K ₂ PtCl ₄	N.A.	cis - [Pt(20) ₂ Cl ₂]	IR ¹ H & ¹⁹⁵ Pt NMR	[44]

169


170 N.A.: Not available

171


172

173


174




21, M = Ni; 22, M = Cu




**23, M = La; 24, M = Nd; 25, M = Eu;
26, M = Gd; 27, M = Tb; 28, M = Dy;
29, M = Tm; 30, M = Y**




31, M = Cu; 32, M = Zn




33




34




35




36




37




38




39




40




41




42




43




44, X = NO₂; 45, X = H; 46, X = Cl




47




48, R = H; 49, R = *p*-CH₃; 50, R = *p*-F;
 51, R = *m*-F; 52, R = *o*-F; 53, R = *p*-Cl;
 54, R = *m*-Cl; 55, R = *o*-Cl; 56, R = *p*-Br;
 57, R = *m*-Br; 58, R = *p*-OCH₃;
 59, R = *p*-NO₂; 60, R = *p*-NMe₂




64, R = Cl; 65, R = OCH₃; 66, R = NO₂;
 67, R = NMe₂




69




70



71



61, L = Cpd 15; 62, L = Cpd 16;
 63, L = Cpd 17



68

175

176

Figure 6. Chemical structures of flavonoid metal complexes

Anti-oxidant activities of flavonoid metal complexes

Complexation of flavonoids with metals often increases the anti-oxidant activity of the parent flavonoids as shown in table 2. Metal complexes demonstrate enhanced activities in free radical scavenging assays such as DPPH \cdot (1,1-diphenyl-2-picrylhydrazyl radical), ABTS $^+$ [2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt)], H $_2$ O $_2$, OH \cdot and O $_2^{\cdot-}$. Superoxide dismutase (SOD) like activity is often used to measure the anti-oxidant activities of the complexes as it is considered to be one of the body's first line free radical defense enzymes.

However, it is important to note that even where the complexes showed better SOD like activity than their free parents they are still far above the limit for good SOD like activity which is IC $_{50} \leq 20 \mu\text{M}$.

Table 2. Summary of anti-oxidant activities of reviewed flavonoids and their metal complexes

Complex	Assay	Results	Ref
		Enhanced activity	
		at 120 μM ,	
23		90%	
24		85%	
25	O $_2^{\cdot-}$	84%	
26		97%	[55]
27		77%	
28		92%	
29		87%	
30		88%	
		<i>quercetin = 42%</i>	
		Enhanced activity	
	DPPH \cdot	at 100 μM , 45%	
		<i>chrysin = 18%</i>	
33			[58, 76]
		Enhanced activity	
	ABTS $^+$	3.96 mM	
		<i>chrysin = 0.9 mM</i>	

	SOD	IC ₅₀ = 157 μ M <i>chrysin = no activity</i>	
	OH \cdot	Enhanced activity at 100 μ M, 75% <i>chrysin = 45%</i>	
36	DPPH \cdot	Enhanced activity at 100 μ M, 40% <i>luteolin = 25%</i>	[65]
	ABTS ⁺	Enhanced activity at 10 μ M, 64% <i>luteolin = 40%</i>	
37	DPPH \cdot	Lower activity IC ₅₀ = >100 μ M <i>luteolin = 66.7 μM</i>	[49]
	OH \cdot	Enhanced activity IC ₅₀ = 17 μ M <i>luteolin = 50.7 μM</i>	
	O ₂ \cdot^-	Lower activity IC ₅₀ = 417 μ M <i>luteolin = 384 μM</i>	
38	DPPH \cdot	Enhanced activity at 1 mM, 90% <i>luteolin = 75%</i>	[70]
	OH \cdot	Enhanced activity at 1 mM, 80% <i>luteolin = 74%</i>	
VOhesperidin	DPPH \cdot ABTS ⁺	No enhancement in activity	[46]
40	DPPH \cdot	Enhanced activity at 10 μ M, 35.5% <i>naringin = 2%</i>	[71]

VOMorin	SOD	Slightly enhanced activity IC ₅₀ = 45 μ M morin = 66 μM	[48]
	DPPH \cdot	Similar activity at 10 μ M, 22% morin = 15%	
	ABTS ⁺	Similar activity at 10 μ M, 81% morin = 76%	
	OH \cdot	Enhanced activity at 10 μ M, 26% morin = 2%	
	ROO \cdot	No effect on radical	
47	OH \cdot	Enhanced activity at 100 μ M, 65% 2 = 43%	[62]
	DPPH \cdot	Lower activity at 80 μ M, 60% 2 = 95%	

188

189 As shown in table 2, rare earth metal complexes (**23-30**) increased O₂ \cdot^- scavenging activity of
190 quercetin by, on average, 2-fold [55]. The difference in activity between the eight metal
191 complexes is not significant, however, the gadolinium complex (**26**) showed the best activity.
192 Whether this increase in activity is attributed to incorporation of the metal atom or to the higher
193 molar ratio of quercetin present in the complex (as opposed to 1 quercetin molecule) needs
194 further investigation. **Figure 7** illustrates the main structural features responsible for the anti-
195 oxidant activity of flavonoids. The 3', 4' *ortho*-dihydroxyl group is the most significant
196 contributor to flavonoids' anti-oxidant activity [3]. These two catechol moieties form *ortho*-
197 semiquinone radicals that are highly stabilized by the electron delocalization and intra-molecular
198 hydrogen bonding. The combination of C2=C3 and 4-C=O group in ring C also assists in the

delocalization of the π -electrons in ring B. This in turn influences the dissociation of phenolic hydroxyl groups as well as the stability of the formed phenoxy radicals in ring B [3]. Ring A *meta*-hydroxyl groups are less important than ring B dihydroxyl groups which are oxidized more readily [77]. The highest increase in activity can be seen upon complexation of metals with flavonoids lacking the essential structural features of anti-oxidant activity (**Figure 7**), such as chrysin and naringin [78]. For instance, complexation of vanadium metal with chrysin (**33**) increased ABTS⁺ scavenging activity from 0.9 mM for chrysin to 3.96 mM [58]. This value is close to that of quercetin (4.7 mM) [79] that fulfills anti-oxidant structural activity requirements (**Figure 7**) and is therefore one of the best flavonoid anti-oxidants.




Figure 7. Summary of structural features responsible for anti-oxidant activity of flavonoids

As illustrated in **Figure 8**, metal complexation demonstrated a positive impact on the DPPH[•] scavenging activity of ligands which was higher than that of vitamin C in only one case, the Cu-Naringin complex **40**. Despite the witnessed increase in DPPH[•] scavenging activity of chrysin (18%) upon complexation with vanadium (**33**) (45%) at 100 μ M, it is still far less than that of ascorbic acid (98%) at the same concentration [58]. However, metal complexation did not always result in enhanced DPPH[•] scavenging activity. The vanadium-luteolin complex **37** showed a loss in the DPPH[•] scavenging activity of luteolin due to chelation of the vanadium metal with the 3' and 4'-OH groups that are essential for anti-oxidant activity of flavonoids [49]. Pi et al. attributed the loss of the polyphenol ligand's (2) high DPPH[•] scavenging activity (95%)

after coordination with germanium (**47**) to steric hindrance factors [62]. This might be caused by the presence of the two ethyl ether groups rather than the germanium atom.




Figure 8. DPPH scavenging activity of metal complexes compared to their parent flavonoids and vitamin C at different concentrations

Cytotoxic activities of flavonoid metal complexes

One of the milestones in the history of chemotherapy was the discovery of cisplatin in 1969 [80]. Cisplatin is effective and still widely used against various types of cancers, such as testicular, ovarian, breast, bladder, lung cancer and brain tumors. It demonstrates remarkable curing rates for testicular cancer (over 90% and near 100% with early discovery) [81]. Inside the body, cisplatin crosslinks DNA and initiates apoptosis. Despite this promising profile, cisplatin suffers from limitations such as nephrotoxicity, neurotoxicity and drug resistance [82, 83]. This ongoing interest in the design and development of metal-based anti-cancer drugs has also influenced the flavonoid field, where a number of flavonoid-metal complexes have been synthesized and evaluated as anti-cancer agents.

Cytotoxic activity of quercetin metal complexes

Table 3. Summary of *in vitro* anti-tumor activity of quercetin metal complexes

Complex	Cell line	Activity (μM) (IC_{50} or suppression % or GI_{50})	Quercetin activity (μM)	Ref.
21	HepG2	14.4 ± 0.9 *	33.7 ± 1.0 *	[84]
	SMMC7721	19.6 ± 0.6 *	42.1 ± 1.0 *	
	A549	35.6 ± 0.8 *	72.1 ± 1.2 *	
22	A549	21.5 ± 0.5 *	34.9 ± 1.0 *	[53]
23	Bel-7402	46.03% ♦	20% ♦	[55]
25	Bel-7402	62.32% ♦	20% ♦	
26	Bel-7402	45.30% ♦	20% ♦	
31	U373MG, PC3, Hop62, HL60, HCT15 and HeLa	< 8.7 •	N.A.	[43]
32	HeLa	7.7 •	N.A.	

* = IC_{50} , ♦ = Suppression % at 10 μM , • = GI_{50}

Hepatocellular carcinoma (HepG2), hepatoma (SMMC7721), lung carcinoma (A549), liver cancer (Bel-7402), central nervous system (U373MG), prostate cancer (PC3), lung cancer (Hop62), leukemia (HL60), colon carcinoma (HCT15) and cervical cancer (HeLa).

It is evident that complexation with metals enhances the anti-proliferative activity of quercetin. Compound **21** (Ni-quercetin) had better activity on the hepatic cancer cell lines (HepG2 and SMMC7721) than on the lung carcinoma cell line (A549). Pro-apoptotic ability has been investigated for complexes **21** and **22** (Cu-quercetin) as a possible cytotoxic mechanism (**Figure 9**) [53, 84]. This is indicated by changes in the levels of key apoptotic proteins like survivin and caspases along with morphological changes observed using the DNA-sensitive Hoechst33258 stain. Possible mechanisms of action of **21** on the A549 cell line were not evaluated. This might have given a better idea of the behavior of complexes in different cell lines and the reasons behind the witnessed difference in activities.




Figure 9. Summary of pro-apoptotic studies done on complexes 21 and 22. Survivin expression was measured by immunocytochemistry and caspase activity by absorption spectra.

Metal atoms in flavonoid complexes can interact with DNA nucleotides by either electrostatic interactions with the phosphate groups, or covalent binding to nucleobases (**Figure 10**). The ROS and free radicals resulting from flavonoids' auto-oxidation are thus generated in proximity to the DNA [37]. This leads to oxidative damage of DNA and induces apoptosis (**Figure 10**) [85, 86]. Flavonoid metal complexes are also more planar than the free ligands which facilitates their binding to DNA via intercalation [37]. Tan et al. reported the selective binding of the nickel quercetin complex (**21**) to GC-rich DNA sequences using fluorescence emission and molecular modelling. This, in addition to decreased survivin activity, led them to conclude that down regulation of survivin via interference with the GC-rich survivin protein promoter gene might be a plausible mechanism by which the complex **21** exerts its anti-tumor activity [84].




Figure 10. Plausible mechanism of oxidative DNA damage by flavonoid metal complexes

The quercetin rare earth metal complexes (**23**, **25** and **26**) showed increased activities compared with free quercetin on the liver cancer cell line (Bel-7402) (**Table 3**) [55]. Complex **23** (La-quercetin) can intercalate with DNA as evidenced by DNA fluorescence studies. Tabassum and her colleagues were able to synthesize two unique hetero-bimetallic complexes quercetin- Cu^{II} - Sn_2^{IV} (**31**) and quercetin- Zn^{II} - Sn_2^{IV} (**32**) [43]. The Cu complex (**31**) showed significant activity on various human cancer cell lines (**Table 3**) except for ovarian cancer (A2780). The Zn complex (**32**), however, did not demonstrate good activity except on the HeLa cell line (**Table 3**). Complexes **22**, **31** and **32** were able to promote the conversion of substrate DNA to cleaved forms (nicked and linear) as studied by gel electrophoresis [43, 53, 54]. To better understand whether this DNA cleavage is promoted through an oxidative pathway, the effect of different radical scavengers was evaluated where only H_2O_2 markedly promoted plasmid DNA breakage caused by the complexes. Increased level of thiobarbituric acid reactive species (TBARS) with increasing concentrations of complex **22** backs up the role of oxidative damage as a mechanism of CT-DNA cleavage [53, 54]. At 30 μM of complex **31**, DNA relaxation activity of

Topoisomerase-I was significantly inhibited. This does not necessarily correlate with direct inhibition of the enzyme and may instead result from strong binding with DNA which prevents the enzyme from exercising its function [43]. To exploit binding of complexes **31** and **32** with the minor groove of DNA, the complexes were docked into the DNA duplex of sequence d(CGCGAATTCGCG)₂ dodecamer (PDB ID: 1BNA). Both complexes bound to the narrow minor groove region of DNA within the GC rich region and were stabilized by hydrogen bonding (2.8–3.0 Å) between the –OH groups of quercetin with O4/N2 atoms of C8/G8 bases in DNA.

Complex **31** also showed good binding modes with the human-DNA–Topo-I complex (PDB ID: 1SC7) and bovine erythrocyte Cu, Zn superoxide dismutase (PDB ID: 2SOD) [43].

Cytotoxic activity of chrysin, luteolin and silibinin metal complexes

Table 4. Summary of *in vitro* anti-tumor activity of metal complexes of chrysin, luteolin and silibinin

Complex	Cell line	Activity (μM) (IC ₅₀ or suppression %)	Flavonoid activity (μM)	Ref.
33	MG-63	16 *	>100 *	[76]
	HT-29	45% ◇	No effect ◇	
VOsilibinin	HT-29	45% ◇	No effect ◇	[87]
34	HepG2	30% ♦	20% ♦	[69]
	Colo205	25% ♦	10% ♦	
	MCF-7	45% ♦	20% ♦	
	MCF-7 10A	15% ♦	10% ♦	
35	A549	73.5 % ♦	4.9 % ♦	[57]
37	A549	60.5 *	66.3 *	[49]
	MDAMB-231	17 *	88.3 *	

* = IC₅₀, ♦ = Suppression % at 10 μM, ◇ = Suppression % at 100 μM

Osteosarcoma (MG-63), colon adenocarcinoma (HT-29), hepatocellular carcinoma (HepG2), caucasian colon adenocarcinoma (Colo205), breast cancer (MCF-7), breast cell line (MCF-7 10A), lung carcinoma (A549) and triple negative breast cancer (MDAMB-231).

The vanadium chrysin complex (**33**) showed significant cytotoxic activity on a human osteosarcoma cell line (MG-63) with an IC_{50} value of 16 μ M (**Table 4**) [76]. This activity is higher than the reported activity of cisplatin on the same cell line (IC_{50} = 28.5 μ M), yet lower than that of doxorubicin (IC_{50} = 3.35 μ M) [88]. According to Leon et al. complex **33** showed a multi-factorial anti-tumor mechanism of action. For example, it demonstrated cytotoxicity to lysosomes and mitochondria of MG-63 cell line (at concentrations from 2.5 to 25 μ M) as evidenced using neutral red (NR) uptake and the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, respectively. Genotoxicity was also evident through induced micronuclei formation and DNA breaks using the Comet assay, in the concentration range 2.5-5 μ M. In addition to that, compound **33** lowered GSH/GSSG ratio in MG-63 cell line especially at higher doses (40%, 50 and 100 μ M). In a protein array platform test, **33** upregulated 82 proteins and downregulated 9 such as PKB/AKT, Cdk 4, 6 and 7, NAK, and JNK [89]. It induced apoptosis via:

- Externalization of the phosphatidyl serine (PS), at the outer plasma membrane leaflet measured by Annexin V-FITC fluorescent probe.
- Alteration of the mitochondria membrane potential (MMP) measured by Rhodamine 123 that leads to the release of cytochrome c and finally to DNA fragmentation.
- Activation of caspase pathway measured by caspase 3 activation (350% basal at 100 μ M).

In another report the anti-tumor activities of vanadium complexes of chrysin (**33**) and silibinin (**VOsil**) were tested on the HT-29 cell line (**Table 4**) [87]. **33** and **VOsil** showed better anti-proliferative activities than cisplatin at 100 μ M (inhibition rate = 12 %) on the same cell line. However, **33** did not show pro-apoptotic effects in the MG-63 cell line despite it causing cell cycle arrest in the G2/M phase after 24 and 48 hours incubation. **VOsil**, on the other hand, increased the percentages of apoptotic/necrotic cells, induced caspase 3 activation and reduced nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) that controls DNA transcription and is aberrantly activated in many cancers. Moreover, **VOsil** fully inhibited topoisomerase-IB using plasmid relaxation assay at 100 μ M. The germanium complex of chrysin, (**34**) also had activity on several targets. Its cytotoxic effect on HepG2, Colo250 and MCF-7 cell lines was not significantly high nor much better than chrysin [69, 90]. The mean apoptotic population detected on MCF-7 and Colo205 cell lines by Annexin-V were 19.5% and

12.5% for 20 µg/ml, respectively. Additionally, cellular ROS production increased in MCF-7 cell line upon addition of high doses of complex **34**. This could be a possible etiology for apoptosis alongside with caspase-3, 8 and 9 activation whose levels increased from 100% to 214.5%, 181.1% and 286.0%, respectively at 20 µg/ml. Some caspase activation was also observed on the Colo205 cell line with an increase from 100% to 129.3%, 146.5 and 119.3%, for caspase-3, 8 and 9, respectively. Cell cycle arrest at the G2/M phase was detected on MCF-7 and Colo205 (high doses) cell lines and at the S phase with low doses of the complex on the Colo205 cell line. Complex **35** (La-chrysin) showed a significant increase (73.5%) in the anti-proliferative activity of chrysin (4.9%) on A549 cell lines. The complex intercalated with DNA base pairs as illustrated by an increase in viscosity and fluorescence of DNA upon addition of complex **35** [57]. The vanadium luteolin complex (**37**) significantly improved the cytotoxic activity of its parent on the MDAMB-231 cell line ($IC_{50} = 17 \mu M$) as shown in table 4 [49]. However, it showed a trivial improvement on the A549 cell line ($IC_{50} = 60.5 \mu M$, luteolin $IC_{50} = 66.3 \mu M$). Naso et al. carried out high content cytotoxicity assays on complex **37** to investigate its mechanism of action on the MDAMB-231 cell line. The tests included ROS production, MMP, plasmatic membrane damage, nuclear membrane damage and mitotic arrest. Complex **37** showed significant increase in the levels of ROS production (650%) and percentage of depolarized cells (20%). Lactate dehydrogenase (LDH) levels in the culture media were measured as an indication for plasmatic membrane damage. Complex **37** demonstrated 212% increase compared with the basal levels as opposed to 98% for luteolin. The vanadium complex (**37**) also showed DNA damage and mitotic arrest activities using H2AX and PHH3 assays, respectively.

Cytotoxic activity of hesperidin, naringin, hesperitin, naringenin, apigenin, morin, kaempferol, warfarin and mendiaxon metal complexes

Table 5. Summary of *in vitro* anti-tumor activity of hesperidin, naringin, hesperitin, naringenin, apigenin, morin, kaempferol, warfarin and mendiaxon metal complexes.

Complex	Cell line	Activity (suppression %)	Flavonoid Activity	Ref.
VOhesperidin	Caco-2	60% (at 100 µM)	No effect	[46]
40	K562	38.4% (at 100 µM)	13.2% (at 100 µM)	[71]
La-18	HL60	50% (at 0.01 µM)	N.A.	[42]
	A549	100% (at 0.003 µM)	N.A.	

39	HeLa	22.5%	15%	[66]
	SGC-7901	45%	30%	
	HepG2	45%	30%	
41	HeLa	24%	27%	
	SGC-7901	25%	33%	
	HepG2	35%	15%	
42	HeLa	25%	10%	
	SGC-7901	45%	5%	
	HepG2	35%	5%	
VOmorin	T47D	43% (at 10 μ M)	No effect	[48]
	SKBR3	38% (at 10 μ M)	14% (at 10 μ M)	
43	EC9706	72% (at 30 μ g/ml)	45 % (at 30 μ g/ml)	[64]
45	HL60	30% (at 100 μ M)	N.A.	[73]

Colon adenocarcinoma (Caco-2), chronic myeloid leukemia (K562), leukemia (HL60), lung carcinoma (A549), cervical carcinoma (HeLa), gastric carcinomas (SGC-7901) and hepatocellular carcinoma (HepG2), breast cancer (T47D), breast cancer overexpressing Herceptin-2 (SKBR3) and oesophageal cancer cell line (EC9706).

As shown in table 5, **VOhesperidin** showed 60% inhibition in cellular proliferation of the colon adenocarcinoma cell line (Caco-2) while its parent hesperidin showed no effect at all on the same cell line at 100 μ M [46]. The Cu naringin complex (**40**) exhibited better inhibition of the K562 cell lines (**Table 5**). Cell cycle analysis showed a 50% decrease in viable cells at the S/G2/M phases after 24 h. The number of hypodiploid cells tremendously increased from 5.5% (control) to 38.4% indicating the complex led to cell death in the first 24 h [71]. The lanthanum complex with ligand **18** exhibited a stronger suppression rate (100% inhibition at 0.003 μ M) than cisplatin (100 % inhibition at 0.004 μ M) on the A549 cell line [42]. Lanthanum complexes like **35** and **La-18** have significantly high suppression rates on A549 cell line.

As shown in table 5, complexation of copper with the flavonoids hesperetin (**39**) and apigenin (**42**) did enhance the anti-proliferative activity of their free flavonoids whilst the naringenin complex (**41**) did not show any improvement except on the HepG2 cell line [66]. **41** and **42** had the same suppression rate (35%) on the HepG2 cell line. This indicates that unsaturation of ring C has no effect on the activity whilst the addition of an OH group on ring B, as in complex **39**, results in 30% increase in the activity. This may be due to the enhanced anti-oxidant activity of

compounds featuring two *m*-hydroxyl groups on ring B (**Figure 7**). Several DNA binding studies (UV-Vis spectral, fluorescence and CD measurements) were performed with the complex **39** that indicated DNA binding via intercalation with higher affinity than the free ligand.

The vanadium morin complex (**VOmor**) showed promising cytotoxic activity on human breast cancer cell lines (**Table 5**). It did not have deleterious effects on the non-tumorigenic breast epithelial mammal cells indicating its selectivity towards cancer cells [48]. Naso et al. suggest that the **VOmor** complex causes cell death by induction of apoptosis. This can be correlated to perturbation of the mitochondrial membrane potential which results in release of cytochrome c from the mitochondria to cytosol. This process leads to the activation of caspases-9, 3 and 7. However, mitochondrial membrane potential was only observed in the SKBR3 cell line which suggests the apoptotic potential on the T47D is achieved via a different mechanism that needs further investigation. The MTT assay was used to determine the anti-proliferative activity of the Kaempferol Zn complex (**43**) on EC9706 cells (**Table 5**) [64]. Cell viability decreased nearly by half in the EC9706 cell line while no significant effect was observed on the normal kidney cells (HK-2 cells). Atomic force microscopy (AFM) morphological data showed that complex **43** could deform and shrink EC9706 cells at the nanoscale. To measure apoptosis induction ability, Annexin V-FITC/PI was used. The apoptosis ratio of EC9706 cells increased from $3.4 \pm 0.9\%$ for control cells to $33 \pm 7.6\%$ upon raise of **43** concentrations from 0 to 30 $\mu\text{g/mL}$, respectively. Complex **43** was able to increase the intracellular calcium ion level in cancer cells that can mediate cell death.

Cytotoxic activity of metal complexes 47-71

Table 6. Summary of *in vitro* anti-tumor activity of complexes 47-71

Complex	Cell line	Activity (μM) (IC ₅₀ or suppression%)	Flavonoid activity (μM)	Ref.
47	HepG2	65% ♦	35% ♦	
51		1.5 *	N.A.	
53	CH1	0.86 *	0.6 *	[67, 68]
54		1 *	N.A.	
55		1.2 *	N.A.	
61	DMBC12	0.96 *	N.A.	[61]

62		1.13 *	N.A.	
63		2.53 *	N.A.	
	DMBC11	4.14 *	N.A.	
64		16 *	17.2 *	
65		28 *	29.5 *	
66	MCF-7	32.1 *	35.4 *	[63]
67		36.2 *	38.4 *	
Ce-19	HL60	21.37 *	N.A.	[75]
69	CCRF-CEM	37.5 *	N.A.	[41]
70	Jurkat	2.97 *	N.A.	
		7.23 *	N.A.	[91]
71	HeLa	7.4 *	N.A.	

* = IC₅₀, ♦ = Suppression % at 160 µM

Hepatocellular carcinoma (HepG2), ovarian cancer (CH1), patient derived (not-established) melanoma (DMBC11 and DMBC12), breast cancer (MCF-7), lung carcinoma (A549), cervical carcinoma (HeLa), chronic myelogenous leukemia (K562), leukemia (HL60), T lymphoblast-like polymorph cancerous cell line (CCRF-CEM) and acute T-lymphoblastic leukemia (Jurkat)

Pi et al. reported the DNA binding of the germanium complex of compound **1** (**47**) [62]. Compound **47** showed an increase in fluorescence emission by 46% (at 550 nm) while that of the free parent **1** showed insignificant increase by 8% (at 536 nm). Intercalation with DNA was also confirmed by a UV absorption method through the hypochromism of complex **47** upon addition of CT-DNA. The anti-proliferative evaluation of **47** on the HepG2 cell line (**Table 6**) was followed by AFM that showed deformation of HepG2 cells and increase in the size of cell membrane particles. The effect on cell cycle, measured by flow cytometry, demonstrated that complex **47** causes cell cycle arrest at the G0/G1 phase.

The ruthenium complexes **48-57** were tested on a number of human cancer cell lines; CH1 (ovarian carcinoma), SW480 (colon carcinoma), and A549 (non-small cell lung carcinoma), human urinary bladder (5637), human large cell lung (LCLC-103H), and human pancreatic carcinoma cell lines (DAN-G) [67, 68]. The most significant anti-proliferative activities were observed on the CH1 cell line with IC₅₀ values ranging from 0.89 to 7.9 µM (**Table 6**) [67]. The SW480 cell line also showed high sensitivity to these complexes (IC₅₀ from 3.4 - 26 µM) while A549 was the least affected with moderate activities (IC₅₀ from 8.6 - 30 µM). Kurzweinhart et al.

attempted to determine the mode of action of complexes **48-57** via CDK2 and topoisomerase II α inhibition assays as well as flow cytometry cell cycle analysis. Despite showing inhibition of CDK2 comparable with the standard reference roscovitine, CDK2 inhibition was excluded by the authors as a mechanism of action. This is due to miscorrelation with the *in vitro* anti-tumor assay activity pattern and poor influence on the G1/S transition of the cell cycle in which CDK2 is involved. On the other hand, complexes **48-57** showed good inhibition of topoisomerase II α catalytic activity at $\geq 10 \mu\text{M}$, which correlated well with the cytotoxic activity (compounds with lowest IC₅₀ in MTT assay showed the highest topoisomerase II α inhibition).

Compounds **61-63** showed promising IC₅₀ values on the patient derived (not-established) melanoma cell lines (DMBC11 and DMBC12) as shown in table 6 [61]. Only complex **63** exhibited potency on both DMABC11 and DMBC12 cell lines (IC₅₀ = 2.53 and 4.14 μM , respectively). Singh et al. developed four flavonoid ruthenium DMSO complexes (**64-67**) and tested their anti-proliferative activities on the MCF-7 cell line (**Table 6**) in addition to their action on different phases of the cell cycle [63]. Both the free ligands, and their ruthenium complexes, showed similar activities with complex **64** being the most potent with IC₅₀ = 16 μM . Analysis of the cell cycle showed that compound **64** dramatically increased the G1 phase and decreased the S phase which might be explained by G1 arrest via inhibition of DNA synthesis in the S phase.

Kostova et al. tested the cytotoxicity of three metal complexes (Cerium, lanthanum and neodymium) with a bis-coumarin (**19**) [75]. Only the cerium complex demonstrated promising anti-proliferative effect on the HL-60 cell line (**Table 6**).

Among four ferrocenylvinyl-flavone derivatives synthesized by Kowalski et al., compound **69** was the most potent (**Table 6**) [41]. The mechanism of action was induction of apoptosis and necrosis as shown by double staining of cells with Hoechst 33258 and propidium iodide. Although anti-tumor activity was evaluated on four human cancer cell lines (HepG2, MCF-7, MDA-MB-231 and CCRF-CEM), CCRF-CEM was the only affected cell line.

Janka and his colleagues also developed a number of ferrocenyl chalcones of which compound **70** showed high activity on Jurkat cell line with IC₅₀ = 2.97 μM (**Table 6**) [91]. Complex **71** has an additional ferrocenyl-vinyl group in its structure, however, it didn't show increase in the

activity on the HeLa cell line ($IC_{50} = 7.4 \mu M$) when compared with complex **70** ($IC_{50} = 7.23 \mu M$).




Figure 11. Summary of the effect of chelating different metals on the anti-proliferative activities of parent flavonoids

It can be deduced from **Figure 11** that 64% of the complexes showed enhanced anti-proliferative activities when compared to their parents while 11% maintained the same activity and 25% had lower activity. It should be noted that not all of the complexes' activities were compared to their respective parent flavonoid, depending on the availability of data. All of iron, zinc and germanium complexes showed higher activity than the free flavonoids. However, the total number of zinc complexes is too low to establish a clear view on the effect of complexation. On the other hand, 84%, 69% and 62% of the vanadium, copper and lanthanum complexes, respectively, exhibited better anti-proliferative activities than the free flavonoid. Ruthenium metal complexes showed inconsistent results as 36% showed enhanced activity while 21% had the same activity and 43% showed lower activities than their parent flavonoids.

Future perspectives

Flavonoids have gained significant interest from researches since the early times. This is due to their therapeutic activities in a broad range of fields alongside their natural abundance, with the anti-oxidant and anti-cancer effects of flavonoids being of the greatest impact. Consequently, flavonoids like quercetin and flavopiridol have reached clinical trials as anti-cancer agents. However, none of them are available on the market as anti-cancer drugs due to their poor

pharmacokinetic profiles. The structural ability of flavonoids to coordinate with metal atoms has provided a new strategy for the development of flavonoid metal complexes with better pharmacological profiles. Although chelation of flavonoids with metals enhanced the anti-oxidant and anti-proliferative activities of their free parents in the majority of cases reported herein, more research is needed to confirm if this is a predictable and general phenomenon. Additionally, more research is required to probe whether this enhancement of activity is sufficient to afford new drugs that offer enhanced clinical outcomes when compared to drugs present in the market for the same indications. Larger scale studies probing the impact of complexing different metal atoms with sets of structurally similar and/or different flavonoids on anti-oxidant and anti-proliferative activities are therefore greatly needed. This would pave the way for a better understanding of their structural activity relationships. Furthermore, the use of computational studies like molecular modelling and quantitative SAR (QSAR) can provide valuable information about possible targets and mechanisms of action of these complexes. This will in turn lead to well informed and targeted structural designs.

Executive summary

Introduction

- Flavonoids are polyphenolic compounds with a C₆-C₃-C₆ ring system.
- Flavopiridol, silibinin and quercetin flavonoids have reached clinical trials as anti-cancer agents for various tumors.
- Flavonoids have poor pharmacokinetic properties which limit their clinical applications.
- Flavonoids have the ability to form metal complexes that can change their pharmacological and pharmacokinetic properties.

Synthesis and characterization of flavonoid metal complexes

- Flavonoid metal complexes are synthesized by reacting alcoholic or aqueous solutions of both the flavonoid and the metal under stirring and/or heating conditions.
- Structural characterization techniques of flavonoid metal complexes are versatile and are often complementary to one another.

Anti-oxidant activities of flavonoid metal complexes

- Flavonoid metal complexes demonstrate better radical scavenging activities than their free parents.
- Anti-oxidant activity is measured by the ability to scavenge free radicals like DPPH[•], ABTS⁺, H₂O₂, OH[•] and O₂^{•-} in addition to measuring SOD like activity.

- Some flavonoid metal complexes showed DPPH[•] scavenging activity higher or comparable to vitamin C.

Cytotoxic activities of flavonoid metal complexes

- The discovery of cisplatin had an important role in directing researchers' focus on the development of metal based drugs.
- Flavonoid metal complexes showed promising results on various human cancer cell lines.
- Cytotoxic activity of flavonoid metal complexes is caused by induction of apoptosis and/or oxidative damage of DNA.
- 64% of the flavonoid metal complexes showed better anti-proliferative activities than their parents, 11% maintained the same activity and 25% had lower activity.

Financial disclosure

MK is grateful to the Newton-Mosharafa Fund for a scholarship that has funded her PhD studies.

References

1. Isoda H, Motojima H, Onaga S, Samet I, Villareal MO, Han J. Analysis of the erythroid differentiation effect of flavonoid apigenin on K562 human chronic leukemia cells. *Chem. Biol. Interact.* 220, 269-277 (2014).
2. Perez-Vizcaino F, Fraga CG. Research trends in flavonoids and health. *Arch. Biochem. Biophys.* 646, 107-112 (2018).
3. Wang T-Y, Li Q, Bi K-S. Bioactive flavonoids in medicinal plants: Structure, activity and biological fate. *Asian J. Pharm. Clin. Res.* 13(1), 12-23 (2018).
4. Jeong HJ, Ryu YB, Park S-J *et al.* Neuraminidase inhibitory activities of flavonols isolated from *Rhodiola rosea* roots and their in vitro anti-influenza viral activities. *Bioorg. Med. Chem.* 17(19), 6816-6823 (2009).
5. Kwon H-J, Kim H-H, Ryu YB *et al.* In vitro anti-rotavirus activity of polyphenol compounds isolated from the roots of *Glycyrrhizauralensis*. *Bioorg. Med. Chem.* 18(21), 7668-7674 (2010).
6. Sithisarn P, Michaelis M, Schubert-Zsilavecz M, Cinatl Jr J. Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells. *Antivir. Res.* 97(1), 41-48 (2013).

- 542 7. Guz NR, Stermitz FR, Johnson JB *et al.* Flavonolignan and Flavone Inhibitors of a
543 Staphylococcus aureus Multidrug Resistance Pump: Structure– Activity Relationships. *J.*
544 *Med. Chem.* 44(2), 261-268 (2001).
- 545 8. Kim YS, Ryu YB, Curtis-Long MJ *et al.* Flavanones and rotenoids from the roots of
546 Amorpha fruticosa L. that inhibit bacterial neuraminidase. *Food Chem. Toxicol.* 49(8),
547 1849-1856 (2011).
- 548 9. Ohemeng K, Schwender C, Fu K, Barrett J. DNA gyrase inhibitory and antibacterial
549 activity of some flavones (1). *Bioorg. Med. Chem. Lett.* 3(2), 225-230 (1993).
- 550 10. Wu T, He M, Zang X *et al.* A structure–activity relationship study of flavonoids as
551 inhibitors of E. coli by membrane interaction effect. *Biochim. Biophys. Acta (BBA)-*
552 *Biomembr.* 1828(11), 2751-2756 (2013).
- 553 11. Eghorn LF, Hoestgaard-Jensen K, Kongstad KT *et al.* Positive allosteric modulation of
554 the GHB high-affinity binding site by the GABAA receptor modulator monastrol and the
555 flavonoid catechin. *Eur. J. Pharmacol.* 740, 570-577 (2014).
- 556 12. Gopinath K, Sudhandiran G. Naringin modulates oxidative stress and inflammation in 3-
557 nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-
558 erythroid 2-related factor-2 signalling pathway. *Neuroscience.* 227, 134-143 (2012).
- 559 13. Spencer JP, Vafeiadou K, Williams RJ, Vauzour D. Neuroinflammation: modulation by
560 flavonoids and mechanisms of action. *Mol. Aspects Med.* 33(1), 83-97 (2012).
- 561 14. Guo L, Hu W-R, Lian J-H *et al.* Anti-hyperlipidemic properties of CM108 (a flavone
562 derivative) in vitro and in vivo. *Eur. J. Pharmacol.* 551(1-3), 80-86 (2006).
- 563 15. Li G, Zhu Y, Zhang Y, Lang J, Chen Y, Ling W. Estimated daily flavonoid and stilbene
564 intake from fruits, vegetables, and nuts and associations with lipid profiles in Chinese
565 adults. *J. Acad. Nutr. Diet.* 113(6), 786-794 (2013).
- 566 16. Greeff J, Joubert J, Malan SF, Van Dyk S. Antioxidant properties of 4-quinolones and
567 structurally related flavones. *Bioorg. Med. Chem.* 20(2), 809-818 (2012).
- 568 17. Hyun J, Woo Y, Hwang D-S *et al.* Relationships between structures of hydroxyflavones
569 and their antioxidative effects. *Bioorg. Med. Chem. Lett.* 20(18), 5510-5513 (2010).
- 570 18. Xie P-J, Huang L-X, Zhang C-H, Zhang Y-L. Phenolic compositions, and antioxidant
571 performance of olive leaf and fruit (*Olea europaea* L.) extracts and their structure–activity
572 relationships. *J. Funct. Foods.* 16, 460-471 (2015).

- 573 19. Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds
574 for anti-cancer therapy. *Int. J. Biochem. Cell. Biol.* 45(12), 2821-2831 (2013).
- 575 20. Ravishankar D, Watson KA, Greco F, Osborn HM. Novel synthesised flavone derivatives
576 provide significant insight into the structural features required for enhanced anti-
577 proliferative activity. *RSC Adv.* 6(69), 64544-64556 (2016).
- 578 21. Liu-Smith F, Meyskens FL. Molecular mechanisms of flavonoids in melanin synthesis
579 and the potential for the prevention and treatment of melanoma. *Mol. Nutr. Food Res.*
580 60(6), 1264-1274 (2016).
- 581 22. Klimaszewska-Wiśniewska A, Hałas-Wiśniewska M, Izdebska M, Gagat M, Grzanka A,
582 Grzanka D. Antiproliferative and antimetastatic action of quercetin on A549 non-small
583 cell lung cancer cells through its effect on the cytoskeleton. *Acta Histochem.* 119(2), 99-
584 112 (2017).
- 585 23. Mirossay L, Varinská L, Mojžiš J. Antiangiogenic effect of flavonoids and chalcones: An
586 update. *Int. J. Mol. Sci.* 19(1), 27 (2017).
- 587 24. Ravishankar D, Watson KA, Boateng SY, Green RJ, Greco F, Osborn HM. Exploring
588 quercetin and luteolin derivatives as antiangiogenic agents. *Eur. J. Med. Chem.* 97, 259-
589 274 (2015).
- 590 25. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human
591 clinical trials. *Invest. New Drugs.* 17(3), 313-320 (1999).
- 592 26. A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute
593 Myeloid Leukemia <https://ClinicalTrials.gov/show/NCT03441555> (April, 22).
- 594 27. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice.
595 *World J Gastroenterol.* 17(18), 2288 (2011).
- 596 28. A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva)
597 and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
598 <https://ClinicalTrials.gov/show/NCT02146118> (May, 23).
- 599 29. Ferry DR, Smith A, Malkhandi J *et al.* Phase I clinical trial of the flavonoid quercetin:
600 pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. *Clin. Cancer Res.*
601 2(4), 659-668 (1996).
- 602 30. Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients
603 With Prostate Cancer Undergoing Surgery <https://ClinicalTrials.gov/show/NCT01912820>
604 (May, 7).

- 605 31. Mulholland P, Ferry D, Anderson D *et al.* Pre-clinical and clinical study of QC12, a
606 water-soluble, pro-drug of quercetin. *Ann. Oncol.* 12(2), 245-248 (2001).
- 607 32. Wu J-W, Lin L-C, Hung S-C, Chi C-W, Tsai T-H. Analysis of silibinin in rat plasma and
608 bile for hepatobiliary excretion and oral bioavailability application. *J. Pharmaceut.*
609 *Biomed. Anal.* 45(4), 635-641 (2007).
- 610 33. Deep A, Marwaha RK, Marwaha MG, Nandal R, Sharma AK. Flavopiridol as cyclin
611 dependent kinase (CDK) inhibitor: a review. *New J. Chem.* 42(23), 18500-18507 (2018).
- 612 34. Gugler R, Leschik M, Dengler H. Disposition of quercetin in man after single oral and
613 intravenous doses. *Eur. J. Clin. Pharmacol.* 9(2-3), 229-234 (1975).
- 614 35. Samsonowicz M, Regulska E, Kalinowska M. Hydroxyflavone metal complexes-
615 molecular structure, antioxidant activity and biological effects. *Chem. Biol. Interact.* 273,
616 245-256 (2017).
- 617 ** This article reviews the synthetic procedures, spectroscopic properties, biological activities
618 and mechanisms of action of hydroxyflavone metal complexes.
- 619 36. Kasprzak MM, Szmigiero L, Zyner E, Ochocki J. Proapoptotic activity in vitro of two
620 novel ruthenium (II) complexes with flavanone-based ligands that overcome cisplatin
621 resistance in human bladder carcinoma cells. *J. Inorg. Biochem.* 105(4), 518-524 (2011).
- 622 37. Kasprzak MM, Erxleben A, Ochocki J. Properties and applications of flavonoid metal
623 complexes. *RSC Adv.* 5(57), 45853-45877 (2015).
- 624 ** This review discusses the different metal coordination patterns, structural properties and
625 the various applications of flavonoid metal complexes.
- 626 38. Grazul M, Budzisz E. Biological activity of metal ions complexes of chromones,
627 coumarins and flavones. *Coord. Chem. Rev.* 253(21-22), 2588-2598 (2009).
- 628 * This review gives details about the mechanisms of action of some metals and flavonoid
629 metal complexes in the treatment of several pathological conditions.
- 630 39. Monserrat J-P, Tiwari KN, Quentin L *et al.* Ferrocenyl flavonoid-induced morphological
631 modifications of endothelial cells and cytotoxicity against B16 murine melanoma cells. *J.*
632 *Organomet. Chem.* 734, 78-85 (2013).
- 633 40. Tiwari KN, Monserrat J-P, Hequet A *et al.* In vitro inhibitory properties of ferrocene-
634 substituted chalcones and auronones on bacterial and human cell cultures. *Dalton Trans.*
635 41(21), 6451-6457 (2012).

- 636 41. Kowalski K, Koceva-Chyla A, Szczupak Ł *et al.* Ferrocenylvinyl-flavones: Synthesis,
637 structure, anticancer and antibacterial activity studies. *J. Organomet. Chem.* 741, 153-161
638 (2013).
- 639 42. Wang B-D, Yang Z-Y, Wang Q, Cai T-K, Crewdson P. Synthesis, characterization,
640 cytotoxic activities, and DNA-binding properties of the La (III) complex with Naringenin
641 Schiff-base. *Bioorg. Med. Chem.* 14(6), 1880-1888 (2006).
- 642 43. Tabassum S, Zaki M, Afzal M, Arjmand F. New modulated design and synthesis of
643 quercetin–Cu II/Zn II–Sn 2 IV scaffold as anticancer agents: in vitro DNA binding
644 profile, DNA cleavage pathway and Topo-I activity. *Dalton Trans.* 42(27), 10029-10041
645 (2013).
- 646 * This article offers the novel synthesis of bimetallic quercetin complexes. It provides a
647 detailed explanation of their anti-cancer mechanism of action supported by the relevant
648 biological assays and computational studies.
- 649 44. Ciesielska E, Studzian K, Zyner E, Ochocki J, Szmigiero L. DNA damage and apoptosis
650 induction in L1210 cells by cis-diamminedichloroplatinum (II) and its new aminoflavone
651 analogue. *Cellular Mol. Biol. Lett.* 5(2), 235-235 (2000).
- 652 45. Weil JA, Bolton JR. *Electron paramagnetic resonance: elementary theory and practical*
653 *applications.* John Wiley & Sons, (2007).
- 654 46. Etcheverry SB, Ferrer EG, Naso L, Rivadeneira J, Salinas V, Williams PaM. Antioxidant
655 effects of the VO (IV) hesperidin complex and its role in cancer chemoprevention. *J.*
656 *Biol. Inorg. Chem.* 13(3), 435 (2008).
- 657 47. Naso LG, Ferrer EG, Butenko N *et al.* Antioxidant, DNA cleavage, and cellular effects of
658 silibinin and a new oxovanadium (IV)/silibinin complex. *J. Biol. Inorg. Chem.* 16(4),
659 653-668 (2011).
- 660 48. Naso LG, Lezama L, Rojo T *et al.* Biological evaluation of morin and its new
661 oxovanadium (IV) complex as antio-xidant and specific anti-cancer agents. *Chem Biol*
662 *Interact.* 206(2), 289-301 (2013).
- 663 49. Naso LG, Lezama L, Valcarcel M *et al.* Bovine serum albumin binding, antioxidant and
664 anticancer properties of an oxidovanadium (IV) complex with luteolin. *J. Inorg.*
665 *Biochem.* 157, 80-93 (2016).
- 666 50. Jurd L, Geissman T. Absorption spectra of metal complexes of flavonoid compounds. *J.*
667 *Org. Chem.* 21(12), 1395-1401 (1956).

- 668 51. Selvaraj S, Krishnaswamy S, Devashya V, Sethuraman S, Krishnan UM. Flavonoid–
669 metal ion complexes: a novel class of therapeutic agents. *Med. Res. Rev.* 34(4), 677-702
670 (2014).
- 671 * This review summarizes the structural characterization techniques and biological
672 significance of flavonoid metal complexes.
- 673 52. Ren J, Meng S, Lekka CE, Kaxiras E. Complexation of flavonoids with iron: structure
674 and optical signatures. *J. Phys. Chem. B.* 112(6), 1845-1850 (2008).
- 675 53. Tan J, Wang B, Zhu L. DNA binding and oxidative DNA damage induced by a quercetin
676 copper (II) complex: potential mechanism of its antitumor properties. *J. Biol. Inorg.*
677 *Chem.* 14(5), 727-739 (2009).
- 678 54. Tan J, Zhu L, Wang B. DNA binding and cleavage activity of quercetin nickel (II)
679 complex. *Dalton Trans.* (24), 4722-4728 (2009).
- 680 55. Zhou J, Wang L-F, Wang J-Y, Tang N. Synthesis, characterization, antioxidative and
681 antitumor activities of solid quercetin rare earth (III) complexes. *J. Inorg. Biochem.*
682 83(1), 41-48 (2001).
- 683 56. Etcheverry SB, Barrio DA, Williams PA, Baran EJ. On the interaction of the vanadyl
684 (IV) cation with lactose. *Biol. Trace. Elem. Res.* 84(1-3), 227-238 (2001).
- 685 57. Zeng Y-B, Yang N, Liu W-S, Tang N. Synthesis, characterization and DNA-binding
686 properties of La (III) complex of chrysin. *J. Inorg. Biochem.* 97(3), 258-264 (2003).
- 687 58. Naso L, Ferrer EG, Lezama L, Rojo T, Etcheverry SB, Williams P. Role of oxidative
688 stress in the antitumoral action of a new vanadyl (IV) complex with the flavonoid chrysin
689 in two osteoblast cell lines: relationship with the radical scavenger activity. *J. Biol. Inorg.*
690 *Chem.* 15(6), 889-902 (2010).
- 691 59. Wang Q, Zhao L, Zhao H *et al.* Complexation of luteolin with lead (II): Spectroscopy
692 characterization and theoretical researches. *J. Inorg. Biochem.* 193, 25-30 (2019).
- 693 60. Kostova I, Manolov I, Nicolova I, Konstantinov S, Karaivanova M. New lanthanide
694 complexes of 4-methyl-7-hydroxycoumarin and their pharmacological activity. *Eur. J.*
695 *Med. Chem.* 36(4), 339-347 (2001).
- 696 61. Pastuszko A, Majchrzak K, Czyz M, Kupcewicz B, Budzisz E. The synthesis,
697 lipophilicity and cytotoxic effects of new ruthenium (II) arene complexes with chromone
698 derivatives. *J. Inorg. Biochem.* 159, 133-141 (2016).

- 699 62. Pi J, Zeng J, Luo J-J, Yang P-H, Cai J-Y. Synthesis and biological evaluation of
700 Germanium (IV)–polyphenol complexes as potential anti-cancer agents. *Bioorg. Med.*
701 *Chem. Lett.* 23(10), 2902-2908 (2013).
- 702 63. Singh AK, Saxena G, Arshad M. Synthesis, characterization and biological evaluation of
703 ruthenium flavanol complexes against breast cancer. *Spectrochim. Acta A Mol. Biomol.*
704 *Spectrosc.* 180, 97-104 (2017).
- 705 64. Tu L-Y, Pi J, Jin H, Cai J-Y, Deng S-P. Synthesis, characterization and anticancer
706 activity of kaempferol-zinc (II) complex. *Bioorg. Med. Chem. Lett.* 26(11), 2730-2734
707 (2016).
- 708 65. Roy S, Mallick S, Chakraborty T *et al.* Synthesis, characterisation and antioxidant
709 activity of luteolin–vanadium (II) complex. *Food Chem.* 173, 1172-1178 (2015).
- 710 66. Tan M, Zhu J, Pan Y *et al.* Synthesis, cytotoxic activity, and DNA binding properties of
711 copper (II) complexes with hesperetin, naringenin, and apigenin. *Bioinorg. Chem. Appl.*
712 2009, (2009).
- 713 67. Kurzwernhart A, Kandioller W, Bächler S *et al.* Structure–activity relationships of
714 targeted RuII (η^6 -p-Cymene) anticancer complexes with flavonol-derived ligands. *J.*
715 *Med. Chem.* 55(23), 10512-10522 (2012).
- 716 68. Kurzwernhart A, Kandioller W, Bartel C *et al.* Targeting the DNA-topoisomerase
717 complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent
718 DNA binder. *Chem. Commun.* 48(40), 4839-4841 (2012).
- 719 69. Yang F, Jin H, Pi J *et al.* Anti-tumor activity evaluation of novel chrysin–
720 organogermanium (IV) complex in MCF-7 cells. *Bioorg. Med. Chem. Lett.* 23(20), 5544-
721 5551 (2013).
- 722 70. Dong H, Yang X, He J, Cai S, Xiao K, Zhu L. Enhanced antioxidant activity,
723 antibacterial activity and hypoglycemic effect of luteolin by complexation with
724 manganese (II) and its inhibition kinetics on xanthine oxidase. *RSC Adv.* 7(84), 53385-
725 53395 (2017).
- 726 71. Pereira R, Andrades NE, Paulino N *et al.* Synthesis and characterization of a metal
727 complex containing naringin and Cu, and its antioxidant, antimicrobial, antiinflammatory
728 and tumor cell cytotoxicity. *Molecules.* 12(7), 1352-1366 (2007).
- 729 72. Manolov I, Kostova I, Konstantinov S, Karaivanova M. Synthesis, physicochemical
730 characterization and cytotoxic screening of new complexes of cerium, lanthanum and
731 neodymium with Nifcoumar sodium salt. *Eur. J. Med. Chem.* 34(10), 853-858 (1999).

- 732 73. Kostova I, Manolov I, Karaivanova M. Synthesis, physicochemical characterization, and
733 cytotoxic screening of new zirconium complexes with coumarin derivatives. *Arch.*
734 *Pharm.* 334(5), 157-162 (2001).
- 735 74. Pastuszko A, Niewinna K, Czyz M, Jóźwiak A, Małecka M, Budzisz E. Synthesis, X-ray
736 structure, electrochemical properties and cytotoxic effects of new arene ruthenium (II)
737 complexes. *J. Organomet. Chem.* 745, 64-70 (2013).
- 738 75. Kostova I, Kostova R, Momekov G, Trendafilova N, Karaivanova M. Antineoplastic
739 activity of new lanthanide (cerium, lanthanum and neodymium) complex compounds. *J.*
740 *Trace Elem. Med. Biol.* 18(3), 219-226 (2005).
- 741 76. Leon IE, Di Virgilio AL, Porro V *et al.* Antitumor properties of a vanadyl (IV) complex
742 with the flavonoid chrysin [VO (chrysin) 2 EtOH] 2 in a human osteosarcoma model: the
743 role of oxidative stress and apoptosis. *Dalton Trans.* 42(33), 11868-11880 (2013).
- 744 77. Chen Y-H, Yang Z-S, Wen C-C *et al.* Evaluation of the structure–activity relationship of
745 flavonoids as antioxidants and toxicants of zebrafish larvae. *Food Chem.* 134(2), 717-724
746 (2012).
- 747 78. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of
748 flavonoids and phenolic acids. *Free Radic. Biol. Med.* 20(7), 933-956 (1996).
- 749 * This review compares the anti-oxidant potential of a range of flavonoid structures giving a
750 detailed idea about the impact of each functional group on the anti-oxidant activity
- 751 79. Pietta P-G. Flavonoids as antioxidants. *J. Nat. Prod.* 63(7), 1035-1042 (2000).
- 752 80. Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of
753 potent antitumour agents. *Nature.* 222(5191), 385 (1969).
- 754 81. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. *Chem.*
755 *Rev.* 107(5), 1387-1407 (2007).
- 756 82. Pil P. Cisplatin and related drugs. *Encyclopedia of Cancer.* 1, 391-410 (1997).
- 757 83. Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of cisplatin mechanisms of
758 action: enhancement of antitumor activity and circumvention of drug resistance. *Chem.*
759 *Rev.* 103(3), 645-662 (2003).
- 760 84. Tan J, Zhu L, Wang B. From GC-rich DNA binding to the repression of survivin gene for
761 quercetin nickel (II) complex: implications for cancer therapy. *Biometals.* 23(6), 1075-
762 1084 (2010).

- 763 85. Kaizer J, Baráth G, Pap J, Speier G, Giorgi M, Réglier M. Manganese and iron
764 flavonolates as flavonol 2, 4-dioxygenase mimics. *Chem. Commun.* (48), 5235-5237
765 (2007).
- 766 86. Sahu SC, Gray GC. Interactions of flavonoids, trace metals, and oxygen: nuclear DNA
767 damage and lipid peroxidation induced by myricetin. *Cancer Lett.* 70(1-2), 73-79 (1993).
- 768 87. León I, Cadavid-Vargas J, Tiscornia I *et al.* Oxidovanadium (IV) complexes with chrysin
769 and silibinin: anticancer activity and mechanisms of action in a human colon
770 adenocarcinoma model. *J. Biol. Inorg. Chem.* 20(7), 1175-1191 (2015).
- 771 88. Naruse T, Nishida Y, Ishiguro N. Synergistic effects of meloxicam and conventional
772 cytotoxic drugs in human MG-63 osteosarcoma cells. *Biomed. Pharmacother.* 61(6), 338-
773 346 (2007).
- 774 89. León IE, Díez P, Etcheverry SB, Fuentes M. Deciphering the effect of an oxovanadium
775 (IV) complex with the flavonoid chrysin (VOChrys) on intracellular cell signalling
776 pathways in an osteosarcoma cell line. *Metallomics.* 8(8), 739-749 (2016).
- 777 90. Yang F, Gong L, Jin H *et al.* Chrysin–organogermanium (IV) complex induced Colo205
778 cell apoptosis-associated mitochondrial function and anti-angiogenesis. *Scanning.* 37(4),
779 246-257 (2015).
- 780 91. Janka V, Žatko D, Ladislav V, Pál P, Janka P, Gabriela M. Some ferrocenyl chalcones as
781 useful candidates for cancer treatment. *In Vitro Cell. Dev. Biol. Anim.* 51(9), 964-974
782 (2015).
- 783
- 784
- 785